Literature DB >> 24997450

Mixed oligomers and monomeric amyloid-β disrupts endothelial cells integrity and reduces monomeric amyloid-β transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model.

Hisham Qosa1, Harry LeVine2, Jeffrey N Keller3, Amal Kaddoumi4.   

Abstract

Senile amyloid plaques are one of the diagnostic hallmarks of Alzheimer's disease (AD). However, the severity of clinical symptoms of AD is weakly correlated with the plaque load. AD symptoms severity is reported to be more strongly correlated with the level of soluble amyloid-β (Aβ) assemblies. Formation of soluble Aβ assemblies is stimulated by monomeric Aβ accumulation in the brain, which has been related to its faulty cerebral clearance. Studies tend to focus on the neurotoxicity of specific Aβ species. There are relatively few studies investigating toxic effects of Aβ on the endothelial cells of the blood-brain barrier (BBB). We hypothesized that a soluble Aβ pool more closely resembling the in vivo situation composed of a mixture of Aβ40 monomer and Aβ42 oligomer would exert higher toxicity against hCMEC/D3 cells as an in vitro BBB model than either component alone. We observed that, in addition to a disruptive effect on the endothelial cells integrity due to enhancement of the paracellular permeability of the hCMEC/D3 monolayer, the Aβ mixture significantly decreased monomeric Aβ transport across the cell culture model. Consistent with its effect on Aβ transport, Aβ mixture treatment for 24h resulted in LRP1 down-regulation and RAGE up-regulation in hCMEC/D3 cells. The individual Aβ species separately failed to alter Aβ clearance or the cell-based BBB model integrity. Our study offers, for the first time, evidence that a mixture of soluble Aβ species, at nanomolar concentrations, disrupts endothelial cells integrity and its own transport across an in vitro model of the BBB.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid-β; Blood–brain barrier; Clearance

Mesh:

Substances:

Year:  2014        PMID: 24997450      PMCID: PMC4133170          DOI: 10.1016/j.bbadis.2014.06.029

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  48 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Authors:  Nicolas Villain; Gaël Chételat; Blandine Grassiot; Pierrick Bourgeat; Gareth Jones; Kathryn A Ellis; David Ames; Ralph N Martins; Francis Eustache; Olivier Salvado; Colin L Masters; Christopher C Rowe; Victor L Villemagne
Journal:  Brain       Date:  2012-05-23       Impact factor: 13.501

Review 3.  Alzheimer's disease: strategies for disease modification.

Authors:  Martin Citron
Journal:  Nat Rev Drug Discov       Date:  2010-05       Impact factor: 84.694

Review 4.  The amyloid hypothesis for Alzheimer's disease: a critical reappraisal.

Authors:  John Hardy
Journal:  J Neurochem       Date:  2009-05-18       Impact factor: 5.372

Review 5.  The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease.

Authors:  R Deane; A Sagare; B V Zlokovic
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 6.  Alzheimer's disease: recent advances and future perspectives.

Authors:  Kiren Ubhi; Eliezer Masliah
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  Beta amyloid effects on expression of multidrug efflux transporters in brain endothelial cells.

Authors:  Katarzyna D Kania; Hasini C Wijesuriya; Stephen B Hladky; Margery A Barrand
Journal:  Brain Res       Date:  2011-08-23       Impact factor: 3.252

8.  Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

Authors:  S A Gravina; L Ho; C B Eckman; K E Long; L Otvos; L H Younkin; N Suzuki; S G Younkin
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

9.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Authors:  T Kawarabayashi; L H Younkin; T C Saido; M Shoji; K H Ashe; S G Younkin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

Review 10.  Pathogenesis of cerebral amyloid angiopathy.

Authors:  Annemieke A M Rensink; Robert M W de Waal; Berry Kremer; Marcel M Verbeek
Journal:  Brain Res Brain Res Rev       Date:  2003-10
View more
  19 in total

1.  High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity.

Authors:  Hisham Qosa; Loqman A Mohamed; Sweilem B Al Rihani; Yazan S Batarseh; Quoc-Viet Duong; Jeffrey N Keller; Amal Kaddoumi
Journal:  J Alzheimers Dis       Date:  2016-07-06       Impact factor: 4.472

Review 2.  Role of RAGE in Alzheimer's Disease.

Authors:  Zhiyou Cai; Nannuan Liu; Chuanling Wang; Biyong Qin; Yingjun Zhou; Ming Xiao; Liying Chang; Liang-Jun Yan; Bin Zhao
Journal:  Cell Mol Neurobiol       Date:  2015-07-15       Impact factor: 5.046

3.  Multi-faceted therapeutic strategy for treatment of Alzheimer's disease by concurrent administration of etodolac and α-tocopherol.

Authors:  Khaled H Elfakhri; Ihab M Abdallah; Andrew D Brannen; Amal Kaddoumi
Journal:  Neurobiol Dis       Date:  2019-01-30       Impact factor: 5.996

Review 4.  Astrocyte and Alzheimer's disease.

Authors:  Zhiyou Cai; Cheng-Qun Wan; Zhou Liu
Journal:  J Neurol       Date:  2017-08-18       Impact factor: 4.849

5.  Characterization of Hit Compounds Identified from High-throughput Screening for their Effect on Blood-brain Barrier Integrity and Amyloid-β Clearance: In Vitro and In Vivo Studies.

Authors:  Khaled H Elfakhri; Quoc-Viet Duong; Courtney Langley; Ashley Depaula; Youssef M Mousa; Trista Lebeouf; Courtney Cain; Amal Kaddoumi
Journal:  Neuroscience       Date:  2018-03-26       Impact factor: 3.590

Review 6.  Neurovascular Alterations in Alzheimer's Disease: Transporter Expression Profiles and CNS Drug Access.

Authors:  Mitchell P McInerney; Jennifer L Short; Joseph A Nicolazzo
Journal:  AAPS J       Date:  2017-05-01       Impact factor: 4.009

Review 7.  Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders.

Authors:  Hisham Qosa; David S Miller; Piera Pasinelli; Davide Trotti
Journal:  Brain Res       Date:  2015-07-15       Impact factor: 3.252

8.  Amyloid Beta 25-35 induces blood-brain barrier disruption in vitro.

Authors:  Elvis Cuevas; Hector Rosas-Hernandez; Susan M Burks; Manuel A Ramirez-Lee; Aida Guzman; Syed Z Imam; Syed F Ali; Sumit Sarkar
Journal:  Metab Brain Dis       Date:  2019-07-02       Impact factor: 3.584

Review 9.  Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease.

Authors:  Veronica Galvan; Matthew J Hart
Journal:  Biochim Biophys Acta       Date:  2015-11-27

10.  Extra-virgin olive oil attenuates amyloid-β and tau pathologies in the brains of TgSwDI mice.

Authors:  Hisham Qosa; Loqman A Mohamed; Yazan S Batarseh; Saeed Alqahtani; Baher Ibrahim; Harry LeVine; Jeffrey N Keller; Amal Kaddoumi
Journal:  J Nutr Biochem       Date:  2015-08-13       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.